Intelligent Bio Solutions Secures Major UK Contract with Multinational Industrial Service Provider

Rhea-AI Summary

Intelligent Bio Solutions (Nasdaq: INBS) announced a major new UK commercial contract on October 23, 2025 with a multinational industrial service provider that employs ~3,000 staff in the UK and Ireland and > 30,000 worldwide. The deployment is described as one of INBS's most significant UK commercial rollouts to date and moves the customer from urine-based third-party testing to INBS's rapid, non-invasive Intelligent Fingerprinting Drug Screening System.

The customer expects faster, less disruptive testing, shorter detection windows, improved employee experience, and on-site rapid results. INBS said this supports recurring cartridge revenue and follows prior deployments across transportation, construction, and mining; INBS reports > 480 accounts in 24 countries and 18 distribution partners. The company is pursuing FDA 510(k) clearance to expand U.S. workplace use beyond Forensic Use Only.

Insights

Commercial Strategy Expert

Large UK enterprise contract should boost recurring revenue and validate commercial model.

Securing a major account with a multinational that employs approximately 3,000 staff in the UK and more than 30,000 worldwide directly expands deployment scale and supports the company’s razor–razor-blade model by increasing consumable cartridge demand over time.

Key dependencies include successful operational roll-out across multiple sites, sustained internal support for replacing urine-based testing, and continued conversion of deployments into recurring cartridge purchases; regulatory progress toward 510(k) clearance for U.S. workplace use also matters for broader market expansion.

Watch adoption traction over the next 6–12 months via new site activations and recurring cartridge order cadence; monitor reported account counts (the company cites over 480 accounts in 24 countries and 18 distribution partners) and any updates on the 510(k) pathway.

Multinational company employs approximately 3,000 staff within the UK and Ireland and more than 30,000 staff worldwide

Large new customer account highlights accelerating adoption of the Company's rapid, non-invasive drug testing technology across high-volume, safety-critical sectors

NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major new contract with one of the United Kingdom's largest industrial service providers.

The multinational company, a global leader operating across the energy, defence, nuclear, and industrial sectors, employs more than 30,000 people worldwide and services complex, safety-critical projects across Europe, the Middle East, and Asia-Pacific. Within the UK and Ireland, the company employs approximately 3,000 staff across multiple sites.

The new customer account represents one of INBS's most significant UK commercial deployments to date. The adoption of INBS’s drug testing technology forms part of the customer’s group-wide change initiative to modernize workforce safety and compliance. The customer's existing testing process, based on urine collection and third-party testing, was identified as slow and operationally disruptive. By transitioning to INBS's Intelligent Fingerprinting Drug Screening System, the customer expects to achieve faster, cleaner, and more efficient testing that reduces downtime, increases productivity, and delivers rapid results at point of testing.

Strong internal support reinforced the transition decision, with stakeholders highlighting the benefits of a less invasive method, improved employee experience, and shorter detection windows. Feedback from customer representatives indicated the move to INBS’s technology was viewed not as a question of if, but when and how, it could be implemented across the organization’s workforce.

“Securing this account highlights the expanding market confidence in our technology and its growing role in transforming drug testing across some of the world's largest industrial operators,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "Each new enterprise adoption validates our value proposition, strengthens our commercial trajectory, and expands recurring consumables revenue potential."

The addition of another global enterprise customer reflects INBS’s continued momentum following multiple deployments across the transportation, construction, and mining sectors. These successes are driving increased adoption of the Company’s razor–razor-blade business model, underpinning long-term recurring cartridge sales and sustained revenue growth.

INBS’s drug testing technology is used by over 480 accounts in 24 countries, with 18 distribution partners expanding its global reach. The Company continues to expand its international footprint while progressing on the regulatory pathway in seeking FDA 510(k) clearance to enter the U.S. workplace testing market beyond the Forensic Use Only category.

About Intelligent Bio Solutions Inc.   

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.   

For more information, visit https://ibs.inc/ 

Forward-Looking Statements  

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.  

Company Contact  

Intelligent Bio Solutions Inc.   
info@ibs.inc 
LinkedIn | Twitter   

Investor & Media Contact  

Valter Pinto, Managing Director   
KCSA Strategic Communications   
PH: (212) 896-1254   
INBS@kcsa.com  

FAQ

What contract did Intelligent Bio Solutions (INBS) announce on October 23, 2025?

INBS announced a major UK contract with a multinational industrial service provider to deploy its Intelligent Fingerprinting Drug Screening System across the customer's UK sites.

How many employees does the INBS customer employ in the UK and worldwide?

The customer employs approximately 3,000 staff in the UK and Ireland and more than 30,000 worldwide.

How many accounts and distribution partners does INBS report as of the October 23, 2025 release?

INBS reported use across more than 480 accounts in 24 countries and 18 distribution partners.

What operational benefits did the customer expect from switching to INBS Intelligent Fingerprinting (INBS)?

The customer expects faster on-site results, less invasive testing, reduced downtime, improved productivity, and shorter detection windows compared with urine-based third-party testing.

Is INBS seeking regulatory clearance to expand into the U.S. workplace testing market?

Yes; INBS is progressing on the regulatory pathway to seek FDA 510(k) clearance to enter the U.S. workplace testing market beyond Forensic Use Only.